Triple agonist: difference between revisions
Diff·revision 10 → 11·01:20, 16 Feb 2025
Difference between revision 10 and revision 11 of Triple agonist. 6 lines changed; the page grew by 95 bytes.
| Revision 10 — 17:57, 28 Jan 2025 GMP_Gita (talk) convert the substitution list to a table so the analogues line up 3,147 bytes +27 | Revision 11 — 01:20, 16 Feb 2025 CiteBot (talk) bot: normalise citation format 3,242 bytes +95 | ||
|---|---|---|---|
| 30 | <ref name="jastreboff2023">Jastreboff AM, Kaplan LM, Frías JP, et al. "Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial." ''New England Journal of Medicine'' 389(6):514–526 (2023). PMID 37366315.</ref> | 30 | <ref name="jastreboff2023">Jastreboff AM, Kaplan LM, Frías JP, et al. "Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial." ''New England Journal of Medicine'' 389(6):514–526 (2023). PMID 37366315.</ref> |
| 31 | 31 | ||
| + | 32 | == See also == | |
| + | 33 | * [[Retatrutide]] | |
| + | 34 | * [[Dual incretin agonist]] | |
| + | 35 | * [[Glucagon]] | |
| + | 36 | * [[Survodutide]] | |
| + | 37 | ||
| 32 | {{DEFAULTSORT:Triple agonist}} | 38 | {{DEFAULTSORT:Triple agonist}} |
| 33 | [[Category:Dual and triple agonists]] | 39 | [[Category:Dual and triple agonists]] |